Clinical Trial Update: High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating high-dose furmonertinib as first-line treatment for EGFR-mutated non-small cell lung cancer with CNS metastases…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING